Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Clinical Pharmacology
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Clinical Pharmacology
    Escitalopram Decreases Symptoms of Major Depressive Disorder in Adolescents: Presented at AACAP - (DGDispatch)
    Cetuximab Continues to Increase Survival in Patients With Head and Neck Cancer for Up to 5 Years - (DGNews)
    Indacaterol Produces Effective Bronchodilation in Patients With COPD During 1 Year of Treatment: Presented at CHEST 2009 - (DGDispatch)
    FDA Approves Romidepsin Injection for Previously Treated T-Cell Lymphoma - (DGNews)
    Long-Term Treatment With Tiotropium Is Effective for Men, Women With COPD: Presented at CHEST 2009 - (DGDispatch)

    News archive

     Recent webcasts/CME - Clinical Pharmacology
    • Optimizing Insulin-Dependent Diabetes Management in Long-Term Care
    • Insulin-Dependent Diabetes in Long-Term Care: Scope of the Problem and Effective Management
    • Insulin-Dependent Diabetes in Long-Term Care: Practical Considerations
    • Patient-Centered Approaches to the Evaluation and Management of Atrial Fibrillation
      Optimizing Antihypertensive Therapy and Health and Economic Outcomes in a Managed Care Environment

      Webcasts/CME archive

       Recent cases - Clinical Pharmacology
        Rapid and Persistent Selection of the K103N Mutation as a Majority Quasispecies in a HIV1-Patient Exposed to Efavirenz for Three Weeks: A Case Report and Review of the Literature
        Reversible Cerebellar Syndrome Caused by Metronidazole
        Complete Remission of Severe Idiopathic Cold Urticaria on Interleukin-1 Receptor Antagonist (Anakinra)
        Rapid Resolution of Nitrofurantoin-Induced Interstitial Lung Disease
        A Patient Presenting with Symptomatic Hypomagnesemia Caused by Metformin-Induced Diarrhoea: A Case Report

        Cases archive
          




        my personal edition > clinical pharmacology > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Rabeprazole/ Levofloxacin/Rifabutin Therapy Equally Effective as Quadruple Therapy in Second-Line Treatment of Helicobacter Pylori

        A DGReview of :"Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection"
        Alimentary Pharmacology & Therapeutics

        03/18/2003
        By David Ball


        Rabeprazole, levofloxacin and rifabutin-based triple therapy is just as effective as quadruple therapy, as second-line treatment for Helicobacter pylori infection, say Chinese researchers.

        The researchers, led by W.M.Wong and colleagues at the Department of Medicine, University of Hong Kong, Queen Mary Hospital, tested the efficacy of the two regimens in 109 patients who had all failed H. pylori eradication earlier. The patients were randomised into two groups.

        The triple therapy group received rabeprazole, 20 mg twice daily; rifabutin, 300 mg once daily; and levofloxacin, 500 mg once daily, for seven days.

        Those in the quadruple therapy group were given rabeprazole, 20 mg twice daily; metronidazole, 400 mg three times daily; bismuth subcitrate, 120 mg four times a day; and tetracycline, 500 mg four times daily, for seven days.

        Endoscopy and culture were performed before treatment.

        Significantly higher resistance rates were found in subjects with previous exposure compared with those with no previous exposure: clarithromycin, 79 vs. 21% ( P < 0.001) and metronidazole, 89 vs. 40% (P < 0.001).

        In the triple therapy group, the intention-to-treat and per protocol eradication rates were 91%/91% and for the quadruple therapy subjects they were 91%/92%.

        The eradication rate for patients in the triple therapy group with double resistance to metronidazole and clarithromycin was 85%, 17 of 20 subjects.

        In the quadruple therapy group the eradication rate for those with double resistance to metronidazole and clarithromycin was 87%,13 of 15 subjects.

        Both regimens showed a compliance rate greater than 95 %.
        Aliment Pharmacol Ther 2003 Feb;17:4:553-60. "Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send